No products in the cart.
GV 971 Sodium Oligomannate
New era for people living with dementia and Alzheimer's disease
GV-971 is the world’s first substance to break new ground in the treatment of Alzheimer’s disease (AD), the most common cause of dementia. Developed after years of intensive research, GV-971 is now at the forefront of innovation, offering hope to millions of people around the world.
GV 971 Sodium Oligomannate
New era for people living with dementia and Alzheimer's disease
GV-971 is the world’s first substance to break new ground in the treatment of Alzheimer’s disease (AD), the most common cause of dementia. Developed after years of intensive research, GV-971 is now at the forefront of innovation, offering hope to millions of people around the world.
Pioneering solutions for treating Alzheimer's disease
The real game changer in the fight against dementia and Alzheimer's disease (AD)
Innovative mechanism
GV-971 works through a unique mechanism to modulate the gut microbiome, reducing inflammation co-responsible for disease
A mixture of acidic oligosaccharides
A substance that restores the balance of the microbiota
Formula that inhibits inflammatory processes
27 years of research
The results of clinical trials unequivocally show improved cognitive function in people with mild to moderate Alzheimer's.
Result of years of research on natural oligosaccharides
Confirmed in multicenter clinical trials
Thousands of patients from around the world
Pioneering solutions for treating Alzheimer's disease
The real game changer in the fight against dementia and Alzheimer's disease (AD)
Innovative mechanism
GV-971 works through a unique mechanism to modulate the gut microbiome, reducing inflammation co-responsible for disease
A mixture of acidic oligosaccharides
A substance that restores the balance of the microbiota
Formula that inhibits inflammatory processes
27 years of research
The results of clinical trials unequivocally show improved cognitive function in people with mild to moderate Alzheimer's.
Result of years of research on natural oligosaccharides
Confirmed in multicenter clinical trials
Thousands of patients from around the world
Medical challenge of our times
Effective response to the devastating consequences of Alzheimer's disease
Alzheimer's disease gradually takes away our most precious things - our memories, our independence, our ability to recognize the people we love. From minor forgetfulness to a profound inability to live independently.
Our latest research opens the door to understanding and treating neurodegenerative diseases. GV-971 works where other therapies fail - by focusing on AD's unique pathway. Take advantage of the treatment and provide your loved ones with hope for a secure future.
It is estimated that more than 50 million people worldwide suffer from Alzhaimer's disease. That number will triple by 2050 to include 152 million patients
Recent studies indicate that people infected with SARS-CoV-2 (COVID-19) virus have a risk of developing AD that is up to 80% higher
Medical challenge of our times
Effective response to the devastating consequences of Alzheimer's disease
Alzheimer's disease gradually takes away our most precious things - our memories, our independence, our ability to recognize the people we love. From minor forgetfulness to a profound inability to live independently. Our latest research opens the door to understanding and treating neurodegenerative diseases. GV-971 works where other therapies fail - by focusing on AD's unique pathway. Take advantage of the treatment and provide your loved ones with hope for a secure future.
It is estimated that more than 50 million people worldwide suffer from Alzhaimer's disease. That number will triple by 2050 to include 152 million patients
Recent studies indicate that people infected with SARS-CoV-2 (COVID-19) virus have a risk of developing AD that is up to 80% higher
Hope for people with Alzheimer's disease and improved cognitive function - available to everyone
GV-971 is a remedy not only for those affected by Alzheimer's disease. In an individualized dose, it leads to significant improvements in memory, concentration and cognitive performance of the mind. It provides an excellent solution for people who are concerned about unleashing their full cognitive potential. GV-971 offers a wide range of benefits for the health of our brain and the neurological processes taking place in it.
clinical study in Shanghai
completed phase III clinical trial
Hope for people with Alzheimer's disease and improved cognitive function - available to everyone
GV-971 is a remedy not only for those affected by Alzheimer's disease. In an individualized dose, it leads to significant improvements in memory, concentration and cognitive performance of the mind. It provides an excellent solution for people who are concerned about unleashing their full cognitive potential. GV-971 offers a wide range of benefits for the health of our brain and the neurological processes taking place in it.
clinical study in Shanghai
completed phase III clinical trial
How did we achieve this?
GV-971 development milestones
1997
The research team led by Prof. Meiyu Geng found the potential carbohydrate compound with drug activity.
2006
Clinical trial registration was completed in China on July, 2006
2007
Launched phase I clinical study in China on December, 2007
2009
Green Valley acquired licensing rights for development of GV-971.
2013
GV-971 Phase II clinical trial was accomplished on August.
2014
Significant milestone for Green Valley’s further development of carbohydrate drug innovation
2018
Completed phase III clinical trial on July, 2018. Center for Drug Evaluation, NMPA accepted the application of new drug on November, 2018
2019
GV-971 officially launched the Chinese market on December.
2020
GV-971 received approval by FDA on the IND application for a global multi-center Phase III clinical study on April.
2021
GV-971 Global Phase III Clinical Trial completed first patient dosed globally on February
2022
GV-971 Gets Included in China National Reimbursement Drug List.
How did we achieve this?
GV-971 development milestones
1997
The research team led by Prof. Meiyu Geng found the potential carbohydrate compound with drug activity.
2006
Clinical trial registration was completed in China on July, 2006
2007
Launched phase I clinical study in China on December, 2007
2009
Green Valley acquired licensing rights for development of GV-971.
2013
GV-971 Phase II clinical trial was accomplished on August.
2018
Completed phase III clinical trial on July, 2018.